Batalla, A
Coto, E
Gómez, J
Eirís, N
González-Fernández, D
Gómez-De Castro, C
Daudén, E
Llamas-Velasco, M
Prieto-Perez, R
Abad-Santos, F
Carretero, G
García, F S
Godoy, Y B
Cardo, L F
Alonso, B
Iglesias, S
Coto-Segura, P
Article History
Received: 19 April 2016
Revised: 25 July 2016
Accepted: 25 August 2016
First Online: 27 September 2016
Competing interests
: Dr Coto-Segura is an invited speaker for and receives grant/research support from Abbvie, Janssen-Cilag, Schering-Plough, Pfizer, Celgene and Novartis. The author have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Dr Daudén has the following conflict of interests: Advisory Board member, consultant, grants, research support, participation in clinical trials and receives honorarium for speaking, with the following pharmaceutical companies: Abbvie/Abbott, Amgen, Janssen-Cilag, LeoPharma, Novartis, Pfizer, MSD-Schering-Plough, Celgene, Lilly. Dr Batalla has participated in clinical trials of Novartis and LeoPharma. Dr Abad-Santos has been a consultant or investigator in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Chemo, Cinfa, Farmalíder, Ferrer, GlaxoSmithKline, Gilead, Janssen-Cilag, Kern, Normon, Novartis, Servier, Teva, and Zambon. Other authors declare no conflict of interest.